Thus, hyperglycemia leading to MEF2A activation is an essential mechanism that may contribute to myocardial remodeling and fibrosis in DCM, and silencing MEF2A may have therapeutic potential in ameliorating these processes. The gene discussed is MEF2A; the disease is familial dilated cardiomyopathy.